Saha, N., Lee, S. G., Brockmann, E.-C., de la Cruz, M. J., Goldgur, Y., Mendoza, R. P., Stanchina, E. de, Love, T. M., Marvald, J., Xu, Y., Xu, K., Himanen, J. P., Lamminmäki, U., Veach, D., & Nikolov, D. B. (2024). Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells. Biomedicine & Pharmacotherapy, 180, 117605. https://doi.org/10.1016/j.biopha.2024.117605

Vaynrub, A., Mishalani, L., Raikhelkar, J., & Crew, K. D. (2024). Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer. Cardio-Oncology, 10(1). https://doi.org/10.1186/s40959-024-00272-8

Therapeutic Efficacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer. (2024). Journal of the College of Physicians and Surgeons Pakistan, 34(06), 682–687. https://doi.org/10.29271/jcpsp.2024.06.682

Bardia, A., Pusztai, L., Albain, K., Ciruelos, E. M., Im, S.-A., Hershman, D., Kalinsky, K., Isaacs, C., Loirat, D., Testa, L., Tokunaga, E., Wu, J., Dry, H., Barlow, W., Kozarski, R., Maxwell, M., Harbeck, N., & Sharma, P. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241248336

Gordon, E., Adeuyan, O., Trager, M., Schreidah, C., Lapolla, B., Fahmy, L., Wesson, K., Magro, C., & Geskin, L. (2023). 212 An un-masking cream: discovery of T-cell dyscrasia after treatment with tapinarof. Journal of Investigative Dermatology, 143(11), S368. https://doi.org/10.1016/j.jid.2023.09.220

Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Baird, J. D., D’Silva, D., O’Keefe, K., Kong, R., Maliakal, P., Gao, L., & Schwartz, G. K. (2023). 1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma. Annals of Oncology, 34, S1039. https://doi.org/10.1016/j.annonc.2023.09.1163

LaRose, M., Zhou, M., Lu, S., Wei, H., Bates, S. E., Schwartz, L., & Fojo, A. T. (2023). 1328P Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib. Annals of Oncology, 34, S766–S767. https://doi.org/10.1016/j.annonc.2023.09.2361

Graff, S. L., Bansal, R., Adeyelu, T., Elliott, A., Bustos, M., Rodriguez, E., Accordino, M., Meisel, J., Gatti-Mays, M., Hsu, E., Lathrop, K. I., Kaklamani, V., Oberley, M., Sledge, G., & Sammons, S. (2023). 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer. ESMO Open, 8(1), 101404. https://doi.org/10.1016/j.esmoop.2023.101404

Loibl, S., Loirat, D., Tolaney, S. M., Punie, K., Oliveira, M., Rugo, H. S., Bardia, A., Hurvitz, S. A., Brufsky, A. M., Kalinsky, K., Cortés, J., O’Shaughnessy, J. A., Dieras, V., Carey, L. A., Gianni, L., Gharaibeh, M., Preger, L., Phan, S., Chang, L., … Piccart, M. J. (2023). Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European Journal of Cancer, 178, 23–33. https://doi.org/10.1016/j.ejca.2022.10.003

Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Diéras, V., Carey, L. A., Gianni, L., Piccart, M. J., Loibl, S., Goldenberg, D. M., Hong, Q., Olivo, M., Itri, L. M., & Kalinsky, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00467-1

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dasgupta, K., & Ramscar, N. (2022). ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 140(Supplement 1), 12204–12205. https://doi.org/10.1182/blood-2022-162451

Fontana, E., Williams, A., Falchook, G., Lakhani, N., Evans, T. R. J., Gondi, V., Iwamoto, F., McKean, M., Symeonides, S., Butowski, N., McLaren, A., Henry, J., Buerki, R., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Wiegert, E., & Bexon, A. (2022). Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. European Journal of Cancer, 174, S82–S83. https://doi.org/10.1016/s0959-8049(22)01018-8

Wenham, R., Ghamande, S., Makker, V., Hou, J., Duska, L., Matei, D., Bhave, M., Scott, R., Hawk, N., Song, T., & Armstrong, D. K. (2022). 2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types. Ovarian Cancer, A312.3-A313. https://doi.org/10.1136/ijgc-2022-esgo.667

O’Shaughnessy, J., Brufsky, A., Rugo, H. S., Tolaney, S. M., Punie, K., Sardesai, S., Hamilton, E., Loirat, D., Traina, T., Leon-Ferre, R., Hurvitz, S. A., Kalinsky, K., Bardia, A., Henry, S., Mayer, I., Zhu, Y., Phan, S., & Cortés, J. (2022). Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 195(2), 127–139. https://doi.org/10.1007/s10549-022-06602-7

Sharma, M. R., Carvajal, R. D., Hanna, G. J., Kang, Y. K., Lee, J., Lee, K. W., Li, B. T., Moore, K. N., Pegram, M., Rasco, D., Spira, A., Wang, D., Weinberg, B. A., Alonso, M., Fang, L., Husain, A., Kowanetz, M., Perez, E. A., & Dumbrava, E. I. (2021). 164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. Annals of Oncology, 32, S1453–S1454. https://doi.org/10.1016/j.annonc.2021.10.183